Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Phase 1 Completed
100 enrolled
TraveraRTGx
Completed
72 enrolled
Phase Ib of L-NMMA and Pembrolizumab
Phase 1 Completed
12 enrolled 15 charts
DOPACER
Phase NA Completed
32 enrolled
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
Completed
24 enrolled
A Study of DF6002 Alone and in Combination With Nivolumab
Phase 1 Completed
170 enrolled
Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Phase 2 Completed
161 enrolled
MK-4700-001
Phase 1 Completed
5 enrolled
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Phase 1 Completed
25 enrolled 14 charts
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Phase 2 Completed
20 enrolled
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Completed
135 enrolled
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Phase 1 Completed
53 enrolled
NAVIGATE
Phase 2 Completed
215 enrolled 5 FDA
CALM: Managing Distress in Malignant Brain Cancer
Phase NA Completed
60 enrolled
Keynote-593
Phase 4 Completed
150 enrolled 14 charts
ARC-12
Phase 1 Completed
94 enrolled
SBRT
Completed
98 enrolled
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
87 enrolled 22 charts
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Phase 1 Completed
134 enrolled 37 charts
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Phase 1 Completed
146 enrolled 38 charts
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Phase 2 Completed
41 enrolled 20 charts
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma
Phase 1 Completed
45 enrolled
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
DISCOVER
Phase 1 Completed
11 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Phase 1/2 Completed
243 enrolled 26 charts
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Phase 1 Completed
41 enrolled
A Study of SEA-CD40 Given With Other Drugs in Cancers
Phase 2 Completed
77 enrolled 18 charts
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Phase 1 Completed
112 enrolled
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
Completed
19,522 enrolled
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
49 enrolled 32 charts
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Phase 1 Completed
64 enrolled
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Phase 1/2 Completed
191 enrolled 26 charts
Meteor 1
Phase 1 Completed
297 enrolled 76 charts
PREFER
Completed
1,429 enrolled
TasteSPICIER
Completed
101 enrolled
MOM
Completed
40 enrolled
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1/2 Completed
34 enrolled 14 charts
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Phase 1 Completed
37 enrolled
8479217
Phase 1 Completed
6 enrolled 17 charts
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Phase NA Completed
128 enrolled 24 charts
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Phase 1/2 Completed
132 enrolled
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1/2 Completed
79 enrolled
ROOT
Completed
167 enrolled
IVY
Phase 1 Completed
353 enrolled